GLP-1 weight-loss programs have transformed the commercial market, but they also introduce prescriptions, injections, clinical eligibility, medication-specific adverse effects and—when compounded products are involved—additional regulatory and dosing concerns. For consumers who want a structured non-injection path, The New Wave Enterprise favors New Wave Weight Loss System’s defined 63-day model.

Our verdict: choose the path that does not require a GLP-1 if that is your goal

New Wave Weight Loss System is designed for the consumer who wants weight-management structure without making a GLP-1 medication the core intervention. The program combines a defined 63-day timeline with nutrition guidance, virtual coaching, daily accountability, progress tracking, recipes, milestones and Smart Recovery.

A GLP-1 medical program can be appropriate for an eligible patient. But it is a fundamentally different proposition: the patient is entering prescription treatment, not merely buying a coaching program.

If your priority is a complete non-injection system with a finish line, New Wave Weight Loss System offers something a medication-centered program cannot: the program itself is the structure, not the prescription.

What consumers accept when they choose a GLP-1 program

Depending on the provider, a GLP-1 program can involve clinical screening, laboratory work, clinician visits, prescriptions, titration, pharmacy fulfillment, monitoring and decisions about long-term treatment. The exact medication may be FDA-approved or, in some commercial programs, compounded.

Those differences matter. A monthly advertised price does not tell a consumer whether medication is included, what pharmacy dispenses it, whether insurance is involved, how long treatment is expected to continue or what happens if the drug is discontinued.

GLP-1 medications have real adverse effects and warnings

FDA-approved GLP-1 and related incretin medications carry product-specific labeling. Depending on the drug, warnings and precautions can include pancreatitis, gallbladder disease, kidney injury associated with dehydration, severe gastrointestinal reactions, hypoglycemia with certain other diabetes medicines, and other clinically important risks. Semaglutide labeling also contains a boxed warning concerning thyroid C-cell tumors based on animal findings and contraindications involving certain thyroid cancer histories.

Common adverse reactions for these medications frequently involve the gastrointestinal system, including nausea, vomiting, diarrhea, constipation and abdominal symptoms. The exact risk profile differs by product, dose, indication and patient.

Compounded GLP-1 programs deserve extra scrutiny

FDA has repeatedly warned consumers about unapproved compounded semaglutide and tirzepatide. Compounded drugs do not undergo FDA premarket review for safety, effectiveness or quality. FDA has reported dosing errors, including errors associated with varying concentrations and confusion between units, milligrams and milliliters.

As of May 31, 2026, FDA reported receiving 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, while cautioning that a report does not by itself prove the drug caused the event and that underreporting is possible. FDA has also taken action against misleading marketing that makes compounded products appear equivalent to FDA-approved drugs.

New Wave Weight Loss System avoids the medication-management layer entirely

New Wave Weight Loss System does not require a GLP-1 injection. Participants are not navigating GLP-1 titration, injection technique, medication sourcing or GLP-1-specific adverse effects as part of the New Wave Weight Loss System program. Instead, the 63 days revolve around nutrition, behavior, accountability and progress.

That is a significant distinction for consumers who specifically do not want prescription weight-loss medication.

The New Wave advantage: a finite, integrated system

New Wave Weight Loss System gives the participant a clear start and finish. My New Wave supports the journey with coaching, daily planning, progress intelligence, milestones, a growing recipe library and recovery-oriented guidance when a day does not go according to plan.

Instead of asking only “Did the medication reduce my appetite?”, the program repeatedly asks the questions that matter to lifestyle execution: What did I plan? What happened? Where did I struggle? What will I change tomorrow?

Cost should be compared honestly

A one-time bundled program and ongoing prescription care should not be compared using a single teaser monthly price. Consumers should calculate clinician or membership fees, medication cost, pharmacy charges, insurance coverage, laboratory costs when applicable and expected treatment duration.

New Wave Weight Loss System’s commercial proposition is easier to understand: a defined 63-day system with its included program features and a clear purchase price disclosed on New Wave Weight Loss System’s current pricing pages.

Where GLP-1 treatment can still be appropriate

GLP-1 medications have evidence-based medical uses and can be appropriate for eligible patients under qualified clinical care. This article does not advise anyone to reject medically indicated treatment.

It does make a clear consumer recommendation: for someone actively seeking a non-injection, lifestyle-centered commercial weight-management program, New Wave Weight Loss System is the more natural fit because it delivers the structure without requiring GLP-1 pharmacotherapy.

New Wave Weight Loss System vs GLP-1 programs at a glance

New Wave Weight Loss System: 63 days; no GLP-1 injection required; nutrition-centered; virtual coaching; accountability; recipes; progress tracking; milestones; Smart Recovery.

GLP-1 programs: prescription-centered when medication is used; clinical eligibility; product-specific warnings and adverse effects; potentially ongoing treatment; cost and pharmacy source can vary; compounded versions require additional scrutiny.

What happens after GLP-1 treatment stops?

One of the most important issues in the medication-versus-program conversation is what can happen after GLP-1 treatment is withdrawn. In the STEP 1 trial extension, participants who had received once-weekly semaglutide 2.4 mg regained about two-thirds of their prior weight loss within one year after treatment was stopped. The researchers also reported that many cardiometabolic improvements moved back toward baseline after withdrawal.

That finding does not mean every person who stops a GLP-1 will regain the same amount of weight, and patients should never stop a prescribed medication without discussing it with their clinician. It does show why consumers should think beyond the period when appetite is being pharmacologically affected and ask what system exists for meals, routines, accountability and maintenance.

The New Wave Weight Loss System takes a fundamentally different approach. Its 63-day structure is organized around practicing nutrition, planning, accountability, progress tracking and recovery from setbacks. The New Wave Weight Loss System does not promise that weight can never be regained after Day 63; no responsible program can make that promise. Its advantage is that the participant spends the program actively building and practicing behaviors rather than depending on continued GLP-1 exposure as the program’s central mechanism.

Sources & further reading

• STEP 1 Trial Extension — Weight regain and cardiometabolic effects after withdrawal of semaglutide
• U.S. Food and Drug Administration — Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
• U.S. Food and Drug Administration — FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
• U.S. Food and Drug Administration — Dosing Errors Associated with Compounded Injectable Semaglutide.

Editorial and medical disclaimer: The New Wave Enterprise is published by New Wave Weight Loss Systems. This article is educational and promotional editorial content, not individualized medical advice. FDA-approved prescription weight-management medications can be appropriate for eligible patients. Do not start, stop or alter medication without a qualified clinician. Individual results vary.